Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Revenue (2016 - 2025)

Haemonetics (HAE) has 17 years of Revenue data on record, last reported at $339.0 million in Q4 2025.

  • For Q4 2025, Revenue fell 2.75% year-over-year to $339.0 million; the TTM value through Dec 2025 reached $1.3 billion, down 4.02%, while the annual FY2025 figure was $1.4 billion, 3.95% up from the prior year.
  • Revenue reached $339.0 million in Q4 2025 per HAE's latest filing, up from $327.3 million in the prior quarter.
  • Across five years, Revenue topped out at $348.5 million in Q4 2024 and bottomed at $225.0 million in Q2 2021.
  • Average Revenue over 5 years is $302.2 million, with a median of $314.8 million recorded in 2023.
  • Peak YoY movement for Revenue: decreased 5.65% in 2021, then rose 24.01% in 2022.
  • A 5-year view of Revenue shows it stood at $239.9 million in 2021, then rose by 27.26% to $305.3 million in 2022, then rose by 10.14% to $336.2 million in 2023, then rose by 3.66% to $348.5 million in 2024, then fell by 2.75% to $339.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $339.0 million in Q4 2025, $327.3 million in Q3 2025, and $321.4 million in Q2 2025.